# US 2026/0083674 A1 · Oxazolidinone liposome compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083674 A1
- Document ID: US20260083674A1
- Status: Published application
- Kind: A1
- Application number: 19/405,695
- Filed: 2025-12-02
- Published: 2026-03-26
- Earliest claimed: 2021-12-22
- Assignees: Akagera Medicines, Inc.
- Applicants: Akagera Medicines, Inc.
- Inventors: Dmitri B. Kirpotin; Alexander Koshkaryev; Charles O. Noble; Daryl C. Drummond
- Web page: https://patentgrep.com/patent/US20260083674A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the disclosure relate to various liposomal compositions of oxazolidinone compounds, and related methods of manufacturing and using the oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability with regard to component degradation.

## Claims

### Claim 1

An AKG-28 liposome composition comprising liposomes, the liposomes comprising AKG-28:
or a pharmaceutically acceptable salt thereof, encapsulated in liposomes comprising hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and methoxy-terminated polyethylene glycol (MW 2000)-distearoylphosphatidyl ethanolamine (PEG(2000)-DSPE).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the liposome encapsulates a sulfate salt of AKG-28.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the liposome is an unilamellar lipid bilayer vesicle.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the liposome vesicle comprises the HSPC, cholesterol, and MPEG(2000)-DSPE, in a molar ratio of 45:55:2.25, encapsulating the AKG-28 sulfate salt.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the liposome vesicle consists of the HSPC, cholesterol, and MPEG(2000)-DSPE, encapsulating the AKG-28 sulfate salt.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is a dispersion of the AKG-28 liposomes in an aqueous medium comprising a deferoxamine chelator.

### Claim 7 (depends on 6)

The composition of claim 6, comprising liposomes having a Z-average diameter of 100-130 nm.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the ratio of AKG-28 free base to the total phospholipid in the liposomes is 280 g/mol.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the AKG-28 liposome dispersion has a pH of 7.3-7.7.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the aqueous medium further comprises a HEPES buffer and isotonic sodium chloride.

### Claim 11

An AKG-28 liposomal liquid dispersion composition comprising a sulfate salt of AKG-28:
encapsulated in a unilamellar lipid bilayer vesicle liposomes formed from vesicle forming lipids consisting of: hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and methoxy-terminated polyethylene glycol (MW 2000)-distearoylphosphatidyl ethanolamine (PEG(2000)-DSPE).

### Claim 12 (depends on 11)

The composition of claim 11, wherein the composition comprises a total of 8.5 mg/mL AKG-28 free base.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the composition comprises a total of 22.6 mg/ml HSPC, a total of 13.6 mg/mL cholesterol, and a total of 4.0 mg/mL MPEG-2000-DSPE.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition further comprises a total of 0.33 mg/ml deferoxamine mesylate.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the composition is a liposomal dispersion in a saline aqueous medium comprising 20 mM HEPES buffer, 144 mM sodium chloride, 0.5 mM deferoxamine, and water for injection at a pH of 7.5, and optionally further comprising sodium hydroxide and hydrochloric acid.

### Claim 16 (depends on 15)

The composition of claim 15, comprising liposomes having a Z-average diameter of 100-130 nm.

### Claim 17 (depends on 16)

A vial comprising the composition of claim 16, packaged with instructions for parenteral administration.

### Claim 18 (depends on 17)

A method of treating a mycobacterial infection, the method comprising parenterally administering to a subject in need thereof a therapeutically effective amount of the AKG-28 liposome composition of claim 17.

### Claim 19 (depends on 1)

A method of making a liposome composition of claim 1, comprising the steps of:
a. dissolving the hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and methoxy-terminated polyethylene glycol (MW 2000)-distearoylphosphatidyl ethanolamine (PEG(2000)-DSPE) in ethanol to obtain a lipid solution;
b. combining the lipid solution of step (a) with an ammonium sulfate trapping agent solution to obtain a lipid suspension;
c. extruding the lipid suspension of step (b) through membranes having defined pore sizes;
d. purifying liposomes from extra-liposomal trapping agent in the extruded lipid suspension to obtain a purified extruded liposome preparation;
e. contacting the liposomes with the AKG-28 compound in an aqueous medium to effect encapsulation of the AKG-28 compound into AKG-28 liposomes;
f. optionally removing unencapsulated AKG-28 compound from the aqueous medium; and
g. providing the AKG-28 liposomes in an aqueous medium comprising a chelator.

### Claim 20 (depends on 19)

An AKG-28 liposomal composition obtained by the method of claim 19, wherein the AKG-28 liposomes are formed by ammonium sulfate gradient at an AKG-28 (free base) to phospholipid ratio of 280 g/mol.
